Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

0P48

Moberg Pharma Ab (publ) (0P48)

Moberg Pharma Ab (publ)

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0P48

<< Previous 1 2 3 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
11/02/2020	08h18	PR Newswire (US)	Moberg Pharma AB Interim Report October - December 2019	LSE:0P48	Moberg Pharma Ab (publ)
04/02/2020	08h13	PR Newswire (US)	Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference	LSE:0P48	Moberg Pharma Ab (publ)
22/01/2020	08h21	PR Newswire (US)	Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015	LSE:0P48	Moberg Pharma Ab (publ)
12/12/2019	08h10	PR Newswire (US)	Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015	LSE:0P48	Moberg Pharma Ab (publ)
09/12/2019	08h15	PR Newswire (US)	Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis	LSE:0P48	Moberg Pharma Ab (publ)
30/10/2019	18h39	PR Newswire (US)	Bulletin from Moberg Pharma's AGM on October 30th, 2019	LSE:0P48	Moberg Pharma Ab (publ)
21/10/2019	07h13	PR Newswire (US)	Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea	LSE:0P48	Moberg Pharma Ab (publ)
18/10/2019	16h16	PR Newswire (US)	Changes to Moberg Pharma's Management Team	LSE:0P48	Moberg Pharma Ab (publ)
30/09/2019	18h18	PR Newswire (US)	Moberg Pharma Proposes to pay the Shareholders SEK 46.50 per Ordinary Share and Repays the MOB-015 Loan	LSE:0P48	Moberg Pharma Ab (publ)
30/09/2019	18h15	PR Newswire (US)	Moberg Pharma and Taisho Sign Exclusive License Agreement for MOB-015 in Japan	LSE:0P48	Moberg Pharma Ab (publ)
30/09/2019	18h15	PR Newswire (US)	Moberg Pharma Proposes to pay the Shareholders SEK 46.50 per Ordinary Share and Repays the MOB-015 Loan	LSE:0P48	Moberg Pharma Ab (publ)
30/09/2019	18h13	PR Newswire (US)	Moberg Pharma and Taisho Sign Exclusive License Agreement for MOB-015 in Japan	LSE:0P48	Moberg Pharma Ab (publ)
15/05/2019	17h43	PR Newswire (US)	Bulletin from Moberg Pharma's AGM 2019	LSE:0P48	Moberg Pharma Ab (publ)
14/05/2019	08h17	PR Newswire (US)	Moberg Pharma AB Interim Report January - March 2019	LSE:0P48	Moberg Pharma Ab (publ)
16/04/2019	08h42	PR Newswire (US)	Moberg Pharma Annual Report 2018	LSE:0P48	Moberg Pharma Ab (publ)
08/04/2019	16h11	PR Newswire (US)	Proposed Management Changes at Moberg Pharma	LSE:0P48	Moberg Pharma Ab (publ)
08/04/2019	16h10	PR Newswire (US)	Moberg Pharma: The Nomination Committee's Proposal to the Annual General Meeting 2019	LSE:0P48	Moberg Pharma Ab (publ)
01/04/2019	08h43	PR Newswire (US)	Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989	LSE:0P48	Moberg Pharma Ab (publ)
29/03/2019	22h09	PR Newswire (US)	Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million	LSE:0P48	Moberg Pharma Ab (publ)
29/03/2019	22h08	PR Newswire (US)	Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million	LSE:0P48	Moberg Pharma Ab (publ)
22/03/2019	08h48	PR Newswire (US)	Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe	LSE:0P48	Moberg Pharma Ab (publ)
15/03/2019	17h14	PR Newswire (US)	Bulletin from Moberg Pharma's Extraordinary General Meeting 15 March 2019	LSE:0P48	Moberg Pharma Ab (publ)
04/03/2019	08h51	PR Newswire (US)	Moberg Pharma Publishes Information Document on the Proposed Divestment of the OTC-Business	LSE:0P48	Moberg Pharma Ab (publ)
13/02/2019	10h23	PR Newswire (US)	Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
12/02/2019	01h48	PR Newswire (US)	Moberg Pharma AB Year-end Report 2018	LSE:0P48	Moberg Pharma Ab (publ)
12/02/2019	01h34	PR Newswire (US)	Moberg Pharma Divests Its OTC-business for USD 155 Million and Secures New Funding for MOB-015 in Transformational Transactio...	LSE:0P48	Moberg Pharma Ab (publ)
11/02/2019	18h13	PR Newswire (US)	Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe	LSE:0P48	Moberg Pharma Ab (publ)
11/02/2019	18h12	PR Newswire (US)	Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe	LSE:0P48	Moberg Pharma Ab (publ)
15/05/2018	20h16	PR Newswire (US)	Bulletin from Moberg Pharma's AGM 2018	LSE:0P48	Moberg Pharma Ab (publ)
08/05/2018	08h21	PR Newswire (US)	Moberg Pharma AB Interim Report January - March 2018	LSE:0P48	Moberg Pharma Ab (publ)

Showing the most relevant articles for your search:LSE:0P48

<< Previous 1 2 3 Next >>

Deutsche Telekom (QX)

BNP Paribas (QX)

Financial Select Sector

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen